SciSparc (SPRC) Stock Price, News & Analysis

Company Overview

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Key Stats

• Today's Range: $7.26 to $7.69
• 50-Day Range: $6.19 to $8.19
• 52-Week Range: $4.14 to $37.59
• Volume: 9,817 shs
• Average Volume: 28,199 shs
• Market Capitalization: $3.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SciSparc Stock Analysis - MarketRank™

SciSparc scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SciSparc.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

SciSparc has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SciSparc does not currently pay a dividend.

Dividend Growth

SciSparc does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.80% of the float of SciSparc has been sold short.

Short Interest Ratio / Days to Cover

SciSparc has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SciSparc has recently decreased by 97.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

SciSparc has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for SciSparc this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SciSparc insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.52% of the stock of SciSparc is held by insiders.

Percentage Held by Institutions

Only 25.06% of the stock of SciSparc is held by institutions.

SPRC Stock Analysis - Frequently Asked Questions

How have SPRC shares performed this year?

SciSparc's stock was trading at $7.56 at the beginning of the year. Since then, SPRC shares have decreased by 3.8% and is now trading at $7.27.

When did SciSparc's stock split?

SciSparc shares reverse split before market open on Thursday, July 3rd 2025.The 1-21 reverse split was announced on Tuesday, June 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of SciSparc?

Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SciSparc own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SciSparc investors own include Solid Power (SLDP), Sangamo Therapeutics (SGMO), Plug Power (PLUG), Mullen Automotive (MULN), NVIDIA (NVDA), Verb Technology (VERB) and Avalon GloboCare (ALBT).

Company Calendar

• Today: 7/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRC
• CIK: 1611746
• Web: scisparc.com
• Phone: 972-3717-5777
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.36
• Quick Ratio: 5.28

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 2.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.13 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 530,000
• Free Float: 527,000
• Market Cap: $3.85 million
• Optionable: Not Optionable
• Beta: 0.72